Company: REVB
Filing Date: 2025-01-13
Form Type: DEFA14A
Source: 0000950170-25-004619
Chunk: 0

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-01-13
Form: DEFA14A
Chunk 0
---
<div align='center'>UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

________________

SCHEDULE 14A

Proxy Statement Pursuit to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

________________</div>

| Filed by the Registrant                    |     | ☒ |
| Filed by a Party other than the Registrant |     | ☐ |

Check the appropriate box:

| ☐ |     | Preliminary Proxy Statement                                                         |
| ☐ |     | Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) |
| ☐ |     | Definitive Proxy Statement                                                          |
| ☒ |     | Definitive Additional Materials                                                     |
| ☐ |     | Soliciting Material Pursuant to §240.14a-12                                         |

<div align='center'>REVELATION BIOSCIENCES, INC.(Name of Registrant as Specified in its Charter)

_________________________________________________________________

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)</div>

Payment of Filing Fee (Check the appropriate box):

| ☒ |     | No fee required.                                                                                    |
| ☐ |     | Fee paid previously with preliminary materials.                                                     |
| ☐ |     | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. |

<div align='center'>Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

– A vote for Proposal 2 saves the Company over $200,000 per year –</div>

San Diego, CA – January 13, 2025 –Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franchise tax fees. All proposals in the proxy are important and the Board of Directors has suggested a vote for all proposals.

Please vote